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ABSTRACT 
Myostatin is a cytokine primarily expressed in skeletal muscle and heart 
muscle and acts as a negative regulator for muscle development. Inhibition of 
myostatin by genetic and pharmacological approaches improves metabolic 
health , which has been generally considered as secondary to the hyper-
muscularity and insulin hyper-sensitivity. Although the receptor for myostatin is 
ubiquitously expressed , whether and how myostatin interacts with other 
metabolically important cell types remain largely unknown. In this work, we 
provide multiple lines of evidence that myostatin directly interacts with 
hepatocytes. Furthermore, we show for the first time that myostatin enhances 
insulin signaling in both cultured hepatocytes and in mouse liver. Mice injected 
with adena-associated virus encoding myostatin propeptide, an endogenous 
myostatin inhibitor, were partially protected from diet-induced liver fat 
accumulation and reduced lipogenic gene expression. Consistent with the in vivo 
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findings , increased lipid accumulation was found in cells treated with myostatin 
peptide or transfected with myostatin construct. Myostatin promotes the lipogenic 
effect of insulin by enhancing nuclear translocation of SREBP-1 c, the master 
lipogenic transcription factor and increases expression of its downstream target 
genes. This effect was found to be associated with myostatin-related mTOR 
activation. Blocking mTOR activation by rapamycin prevents myostatin-
associated increase of nuclear SREBP-1 c and its downstream lipogenic 
enzymes. In summary, this work identified liver as a direct target of myostatin , 
providing the first evidence that myostatin has opposite impacts on insulin 
signaling in muscle cells and hepatocytes. Our data also provided a novel 
mechanism for the long-term metabolic protection afforded by anti-myostatin 
treatments demonstrated in this work as well as elsewhere. 
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent 
chronic liver disease in the population 1·2 . The prevelance of NAFLD in the 
general population reaches 15-20%3•4 . NAFLD affects from 2.6% to 9.8% of 
children and adolescents, and this figure increases up to 74% among obese 
individuals2•5. Abundant evidence indicates that NAFLD is often associated with 
obesity, type 2 diabetes, dyslipidemia, and most patients have evidence of 
systemic insulin resistance. 
The development of fatty liver are considered as the effects of oxidative stress 
and insulin resistance associated with obesitl. Paradoxically, insulin resistance 
leads to hyperinsulinemia, which cause hyperactive lipogenic effect in liver, 
promoting the synthesis of FAs from glucose and hepatic triacylglycerols (TAGs) 
storage7. However, the mechanisms involved in the accumulation of TAGs in the 
liver and subsequent hepatocellular damage are not fully understood. Studies in 
mice with liver-specific deletion of insulin receptor clearly indicate that insulin 
signaling is indispensible for NAFLD development8·9. Studies on humans with 
insulin-secreting tumors and pancreatic islet cell transplants provided additional 
evidence that insulin directly promotes fat accumulation in liver cells 10 . Despite 
the high prevalence NAFLD, the only accepted therapy for pediatric NAFLD is life 
style modification with diet and physical exercise. There is no effective medical 
treatment for this complex disease. From prior studies on transgenic mouse 
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models, anti-myostatin has emerged as an effective strategy to counteract diet-
induced NAFLD11 . 
Myostatin was first discovered as a negative inhibitor of muscle development by 
McPherron and Lee12 . The myostatin null mice have increased muscle mass and 
reduced muscle fat , with improved glucose metabolism 13 . Constitutive myostatin 
knock-out mice are resistant to diet-induced obesity, insulin resistance and 
NAFLD14-16 . It was later shown that postnatal transgenic expression of myostatin 
propeptide, an endogenous myostatin inhibitor, also leads to hyper-muscularity 
and resistance to diet-induced obesity17•18• Furthermore, mice with adult age 
myostatin deletion are still protected against diet-induced NAFLD, even though 
they gain equal amount of fat mass as the control13 . Similar metabolic protection 
can be achieved by muscle-specific myostain blockade but not by fat-specific 
myostatin blockade 19·20 . These findings suggest that in vivo anti-steatosic effect 
of myostatin blockade could be secondary to the improvement of muscle function 
after myostatin blockade, which leads to improved systemic fuel metabolism. 
Several prior studies also suggested that myostatin may directly interact with the 
liver. Wilkes et al first reported that constitutive myostatin blockade improves 
insulin-mediated suppression of hepatic glucose output21 . The same study also 
shows that injection of recombinant myostatin increases serum TN Fa and 
caused insulin intolerance21 . Hittel et al reported that injection of recombinant 
myostatin daily for 7 days leads to systemic insulin intolerance and impaired 
insulin signaling in the liver, although this group did not find a significant change 
2 
in TNFa22 . In addition , Akpan et al reported that injection of soluble receptor for 
myostatin for 4 weeks results in better suppression of hepatic glucose output in 
response to insulin treatment23. While some of these reported hepatic effects are 
independent of changes in muscle or fat mass, all reported parallel changes in 
insulin sensitivity in skeletal muscle, which may lead to profound changes in 
systemic metabolism in the absence of changes in muscle or fat mass 11 ·21-23 . 
Also, endogenous myostatin circulates in a latent form protected by its own 
propeptide dimme~4 . So another key question is whether the liver is capable of 
activating the latent myostatin complex11 . In addition, hepatic lipid synthesis, 
glycolysis and lipogenesis are mediated by the activation of different transcription 
factors such as sterol regulatory element binding protein 1 c (SREBP-1 c) , 
peroxisome proliferator-activated receptor y (PPAR- y) and carbohydrate 
responsive element-binding protein (ChREBP). It still remains to be determined 
as whether and how myostatin plays a direct role in regulation of hepatic insulin 
signaling and hepatic metabolic regulations. In this work, we will address these 
questions by studying the effect of myostatin and its blockade on cultured 
hepatocytes and animals after short-term and long-term treatments. 
3 
MATERIALS AND METHODS 
Material 
A protease-resistant myostatin propeptide mutant (D76A) fused with mouse lgG-
Fc was a gift from Dr. Se-Jin Lee (Johns Hopkins University). The recombinant 
product of this construct (D76A-Fc) has been shown to increase skeletal muscle 
mass in adult mice. The construct was used to generate an adena-associated 
virus (AAV9) , using a commercial service (Vector Biolabs, Philadelphia, PA) , to 
achieve sustained ectopic expression of D76A for myostatin inhibition . This gene 
transfer strategy has been employed by several other groups to facilitate 
myostatin inhibition and improve muscle development in mice. 
Recombinant myostatin was supplied by Amgen Inc (Thousand Oaks, CA) and 
myostatin propeptide was purchased from R&D Systems (Minneaplis , MN); both 
were of mammalian origin. Adenovirus of full-length and the control virus of 
truncated dominant negative myostatin , both fused with eGFP, were gifts from 
Dr. A Rosenzweig (Harvard Medical School). Plasmids containing full length 
activin receptor 118 (pCMV5-ActRIIB) , the high affinity membrane receptor for 
myostatin, and retroviral vector encoding dominant negative Smad3 (pLPCX 
Smad oSSVS) were obtained from Addgene (Cambridge, MA). Dominant 
negative Act liB (aa 1-211) was .generated by PCR cloning and subsequently 
inserted into retroviral vector pLPCX. 
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Antibod ies for phosphor-AMPKTh172, phosphor-ACCser79, phospho-Aktser473, 
phosphor-p70S6K, AMPK, and ACC were from Cell Signaling Technology 
(Danvers, MA). Antibodies against Smad2/3, 13-tubulin, 13-actin and GAPDH were 
from Santa Cruz (Santa Cruz, CA). All other supplies were from conventional 
vendors. 
Animals and diet 
The animal protocols were approved by IACUC of Boston University. Male Ldlr 
null mice were from Jackson Laboratory (Bar Harbor, Ml) . At eight weeks of age, 
mice were analyzed by NMR for body composition, and divided into two groups 
of similar mean body composition. Animals were injected through tail vein with 
either vehicle saline or AAV-D76A (4x1011 vg/ea) . This dosage has been shown 
to raise muscle mass in mice. AAV with no functional gene products does not 
cause phenotype change in Ldlr-1- mice. 
This was confirmed in our preliminary studies with AAV-eGFP (not shown) . 
Animals were maintained on regular chow diet for 7 weeks to stabilize post-
injection body composition . All mice were then switched to high fat diet 
.. 
(TD.09547, Harlan Laboratories, Madison WI) for 12 weeks. This diet contains 
48.4%, 21.4%, and 30.1% calories from carbohydrate , protein , and fat, 
respectively. 
Ectopic expression of myostatin propeptide mutant and body composition 
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To achieve long-term myostatin blockade, we injected wild-type mice with 
myostatin pro peptide mutant using the AA V-mediated gene transfer technique. 
This strategy has been shown to remain effective in mice for over 13 months. 
Tissue analysis shows that injection of AA V9-D76A largely increased pro peptide 
expression in the liver. No difference in expression of propeptide was detected in 
muscle. This is probably because i.v. delivery of the virus and the high affinity of 
AA V9 for hepatocytes, as well as the high expression rate of endogenous 
myostatin in muscle that can easily mask the ectopic gene expression if there is 
any. 
Pyruvate and insulin tolerance tests 
Pyruvate and insulin tolerance tests were done on 8-12 mice per treatment group 
at 18 weeks of age after an overnight/5-hour fast. For the pyruvate tolerance test, 
following an 18-h fast, mice received an i.p. injection 2 g/kg of sodium pyruvate 
(Sigma) dissolved in PBS. Insulin sensitivity test were done by intraperitoneal 
injection of human insulin (Lily, Indianapolis, IN) at a dose of 0.75 U/kg body 
weight. Two blood drops from tail were taken at 0, 15, 30, 45, 60, 75 and 90 min 
after insulin injection for measuring blood glucose by Accu-Check glucose 
monitor (Roche Diagnostic, Indianapolis, IN) in duplicate. 
Cell culture 
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Adenovirus transfection was done as described before. Virus-mediated 
expression of myostatin mature peptide was confirmed by real-time PCR. 
MMHD3 hepatocytes were generated as described before. These cells were 
grown in RMPI 1640 medium containing 10% fetal bovine serum (FBS) and IGFII 
(4 ng/ml) , EGF (14 ng/ml) and insulin (2 .5 j.Jg/ml) , and supplements. After 48 
hours, the cells were switched to RPM I 1640 with 1% FBS for two hours before 
treatments with myostatin (1 00 ng/ml) and AI CAR (0.2 mM). To generate stable 
cell lines expressing mstn, dominant negative ActRIIB and dominant negative 
Smad3, the corresponding retrovirus were prepared by transfection of the viral 
vectors into the packaging cells. Viral supernatants were filtered and added to 
growing MMHD3 hepatocytes. Stable cell lines were established after selection 
with puromycin . 
Lipid droplet staining 
Cells were stained with BODIPY as previously described. Briefly, BODIPY stock (1 
mg/ml, in DMSO) was mixed to the differentiation medium (5 ug/ml) ·and used for 
cell incubation for 4 h. Cells were then washed with cold PBS containing 0.1% BSA 
for 4 times. After washing, the majority of the fluorescence was found to be 
associated with lipid droplets. The intracellular fluorescent intensity was then read 
on the plate reader at 530/550 nm. 
Assays for de novo fatty acid synthesis 
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Similarly, HepG2 cells were incubated with myostatin (1 00 ng/ml) for 24 h and [1 , 
2-14C] acetic acid was added for the last 3 h of incubation. Lipid extracts were 
separated by TLC (Hexane: ether: acetic acid at a ratio of 70:30:1) and visualized 
under iodine vapor. The triglyceride-incorporated radioactivity was counted as 
the index for fatty acid synthesis. 
Western blotting analysis 
Cells were washed by cold PBS buffer and prepared for immunoblot analysis in a 
lysis buffer (50mM Tris-HCI, Ph7.5, 1mM EDT A, 1mM EGTA, 10% glycerol , 1% 
Triton-X, 50mM NaF, 5mM Na pyrophosphate, 1 mM Na3V04, 0.1 %SDS, 1 mM 
PMSF, 1 mM OTT) . Protein concentration was qualified with Bradford method (Bio-
Rad laboratories, Inc. Hercules,CA), and equal amount of protein (50ug) was 
separated by SDS-PAGE. Proteins were transferred to a polyvinylidene difluoride 
membrane and used for Western analysis following the stand protocol. Primary 
antibodies and secondary antibodies were purchased from Santa Cruz or Cell 
Signaling (Danvers, MA). Proteins were visualized using chemiluminescence 
reagent (Pierce, Rockford, IL) and quantified by densitometry. 
Real-time PCR analysis 
Total RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA). For reverse 
transcription, 1 ug of the total RNA was converted to first-strand complementary DNA 
in 20ul reactions using AffinityScript Q-PCR eDNA Synthesis kit (Agilent 
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Technologies, La Jolla, CA), wh ich was subsequently diluted five times. For PCR 
sample preparation, 5ul of eDNA was mixed in 20ul reaction volume with 1 OuM 
primer and SYBR master enzyme mix (SABiosciences, Frederick, MD). The reaction 
was initiated at 94°C for 10minutes, fol lowed by 40 cycles through 94°C 15seconds 
and 60°C 1 minute. All reactions were performed in duplicate. All CT values were in 
the range of 20-30 cycles . Amplification curves were analyzed using SDS 1.9.1 
software (Applied Biosystem, Forster City, CA). HPRT controls provided relative 
gene expression levels. 
Statistical data analysis 
All numerical results are presented as means +/- se. Comparison between two 
treatments were done using Student's t test. Comparison among three or more 
treatments was done by One-way ANOVA fol lowed with Turkey's test for pair 
comparison. 
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RESULTS 
Long-term myostatin blockade protects wild-type mice from diet-induced 
liver fat accumulation and hepatic insulin resistance. 
Several previous studies have documented that genetic inhibition of myostatin in 
mice results in protection against diet-induced fatty liver13•14·20•21 . To determine 
the translational value of these prior findings, we treated wild-type adult mice with 
AA V9-D76A. As shown in Figure 1, myostatin blockade resulted in significantly 
less lipid staining (Figure 1A) and lower liver triglyceride content (Figure 1 B). This 
effect was associated with reduced expression of liver lipogenic genes and their 
master transcription factor SREBP-1 c (Figure 1 C). Measurement of selected key 
elements in hepatic lipid oxidation pathway shows no detectable difference 
(Figure 1 C, lower panel) . 
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Figure 1. Compared with wild type mice fed a high fat diet, AAV-mediated long-term 
myostatin blockage reduces liver fat accumulation (A, B) and reduces hepatic lipogenic 
gene expression (C) . Staining images are representative of N = 3 for each group and the 
bar graphs are means of N = 8-10. 
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Consistent with its effect on reduced liver fat store, long-term myostatin 
blockade results in lower plasma triglyceride concentration and a trend of lower 
plasma free fatty acids but with no significant difference in fasting insulin and 
glucose (Figure 2A). We performed insulin tolerance test and pyruvate 
tolerance test to assess the effect of myostatin blockade on systemic and liver-
specific insulin resistance. As shown in Figure 28, myostatin blockade resulted 
in a lowering of non-fasting blood glucose but did not affect the percentage of 
insulin-mediated glucose lowering. In contrast, we found that long-term 
myostatin blockade significantly reduced pyruvate-induced rise of plasma 
glucose (Figure 28, right panel). Since fasting insulin was the same, lowering of 
pyruvate conversion to glucose suggests better insulin-mediated suppression of 
gluconeogenesis in the liver. This is also consistent with increased hepatic 
expression of insulin receptor substrate 2 (IRS-2) and decreased expression of 
phosphoenolpyruvate carboxykinase (PEPCK) in mice injected with AA V9-
D76A (Figure 2C), both are key elements in insulin-mediated regulation of 
gluconeogenesis25 . 
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Figure 2. Long-term myostatin blockage results in moderate improvement of plasma 
lipid profile (A) with no significant impact on insulin tolerance but significantly reduced 
hepatic glucose output during fasting when stimulated by acute increase of exogenous 
pyruvate (B) . Mice injected with AAV9-D76A had higher hepatic expression of insulin 
receptor substrate 2 (IRS-2) and lower expression of phosphoenolpyruvate 
carboxykinase (PEPCK) (C) . 
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Short-term myostatin administration enhances hepatic insulin sensitivity 
and activates SREBP-1c. 
While the correlation between excessive liver fat store and insulin resistance is 
well established, the cause-and-effect relationship remains controversial. To 
determine the effect of myostatin on hepactic insulin sensitivity before the 
formation of fatty liver, we studied the animals one week after injection of 
adenovirus encoding a full-length myostatin construct (FL-mstn) . Control was 
injected with a parallel vira l stock encoding a truncated myostatin construct 
(DN-mstn). As shown in Figure 3A, pyruvate-stimulated glucose production was 
lower in mice injected with FL-mstn than in mice injected with DN-mstn , implying 
that administration of full-length myostatin does not cause short-term 
impairment of hepatic insulin sensitivity, and may ever enhance insulin singaling 
as stated in legend. Western analysis shows that compared to DN-mstn , mice 
treated with FL-mstn had higher level of phosphorylated (activated) Akt at both 
Th308 and Ser473 residues in the liver. Liver expression of phosphor-
mammalian target of rapamycin (mTOR) at Ser2248 residue, a well-established 
master anabolic regulator downstream from the insulin/PI3K/Akt signaling 
pathwa/6 , was also largely increased in response to FL-mstn (Figure 38) . This 
was associated with increased phosphorylation of S6 and 4EBP1 , both are 
established marker for mTOR activation27·28 . Previous studies have shown that 
mTOR plays a key role in insulin-induced activation of SREBP-1 c and the 
14 
expression of its downstream target SCD-1 29 . As shown in Figure 3C, mice 
treated with FL-mstn had a higher level of nuclear form (active) of SREBP-1c as 
well as its downstream target SCD-1, an enzyme that plays a critical role in 
regulating hepatic lipogenesis29 . Our findings of myostatin-induced activation of 
mTOR and its downstream SREBP-1c predict that myostatin may promote 
hepatic lipogenic activity and liver fat accumulation. This is consistent with our 
observation that long-term myostatin blockade attenuated diet-induced fatty 
liver development (Figure 1 ). 
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Figure 3. Short-term adenovirus-mediated myostatin expression in vivo enhances 
hepatic insulin signaling as evidenced by (A) increased suppression of glucose output, 
(B) increased phosphorylation of Atk and mTOR as well as downstream targets (C) , and 
(D) increased nuclear level of the master lipogenic transcription factor SREBP-1 c and its 
downstream target SCD-1. 
Myostatin directly targets hepatocytes through activin receptor liB. 
While the results shown in Figures 1-3 suggest a direct impact of mysotatin on 
hepatic insulin signaling , the mechanism for such in vivo findings can be 
complex and confounding. To investigate the physiological relevance of the 
hepatic effect of myostatin , we tested whether liver expresses myostatin as well 
as its receptor. As shown in Figure 4A, myostatin is abundantly expressed in 
muscle but minimally in the liver, in agreement with the previous studies 12. 
However, activin receptor liB (ActRIIB)30, the primary myostatin receptor, was 
found to be expressed to a significant extent in the liver (Figure 4A, right panel) . 
Furthermore, we found that expression of ACtRIIB in cultured hepatocytes can 
be induced by incubation with recombinant myostatin (Figure 4A, lower panel) . 
To test whether myostatin interacts with hepatocytes with biological activity, we 
measured the effect on phosphorylation of Smad2/3, a well-established 
downstream target of myostatin/ActRIIB31 •32. As shown in Figure 48, incubation 
with myostatin resulted in robust increase in phosphor-Smad2/3. Interestingly, 
this effect was largely blocked in hepatocytes expressing a truncated receptor 
(dn-RIIB) , implying active receptor-mediated interaction between myostatin and 
16 
hepatocytes. Using a luciferase reporter 3TP-Luc which contains the response 
elements derived from the promoter of TGFI3-responsive gene PAI-1, we show 
that myostatin directly stimulates transcription of this reporter gene (Figure 4C, 
left panel) . Consistently, we show that treatment with myostatin increased 
mRNA expression of PAI-1 and TGFI31 (Figure 4C, right panel). Finally, to 
determine whether hepatocytes are capable to respond to endogenously 
produced myostatin , we established a stable cell line of hepatocytes expressing 
a full length myostatin construct. As shown in Figure 40 , expression of FL-mstn 
results in constitutive phosphorylation of Smad3. Together, these results 
indicate that hepatocytes can be a direct target of myostatin . Of note, the 
presence of myostatin propeptide is critical for the proper folding of myostatin 
mature peptide dimmer33 . Hence, our findings that hepatocytes responded to 
ectopic FL-mstn similarly to recombinant myostatin suggest that hepatocytes 
are capable to activate latent myostatin complex, the physiological form of 
myostatin in circulation. 
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Figure 4. Myostatin expression is lower in the liver, but its receptor is expressed 
significantly up regulated (A). Exogenous myostatin directly interacts with hepatocytes to 
activate Smad2/3 signaling (B) which drives the reporter luciferase activity (C). Over-
expression of full-length myostatin results in consitutive activation of Smad3 (D). 
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Myostatin induces lipogenesis in cultured hepatocytes. 
After identification of hepatocytes as a novel target of myostatin, we then tested 
whether myostatin may directly participate in regulation of hepatic lipogenesis. 
To accelerate lipid accumulation, we created an artificial exogenous condition 
with elevated concentration of insulin, glucose, and a liposome complex, 
mimicking the hormonal and nutritional condition typical of diet-induced obesity. 
As shown in Figure 5A, incubation with recombinant myostatin increased the 
number and size of lipid droplets formed in hepatocytes. Similar effect was 
found in hepatocytes expressing ectopoic FL-mstn (Figure 5A, lower panel) . 
Quantitative lipid staining shows that myostatin caused about two fold increase 
in fat store after 4 days exposure to the obesogenic environment (Figure 58, left 
panel). Using isotope tracing method, we also found an increased rate of fatty 
acid synthesis in hepatocytes exposed to exogenous myostatin (Figure 58, right 
panel) . Consistent with the in vivo findings shown in Figure 3, we also found 
that myostatin was capable to increase nuclear SRE8P-1 c and its downstream 
lipogenic enzyme FAS and SCD-1 in cultured hepatoctyes(Figure 5C). 
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Figure 5. Both exogenous and ectopic myostatin increases lipid accumulation in 
cultured hepatocytes (A, B) and increases expression of SREBP-1 C induced lipogenic 
enzymes (C). 
MMHD3 cells stably transfected with FL-mstn or pLPCX, grown to confluence in 8% FBS 
for 2 days, refresh with 8% FBS for 6 hours, and treat with insulin 80ug/ml, glucose 15 
mmol/ml, liposome 0.04% for 16 hours. 
Myostatin induces opposite response to insulin in hepatocytes and 
myoblast. 
Since our findings that myostatin directly increased insulin signaling and 
lipogenic activity in hepatocytes appear to be in direct contrast to the well-
established consensus that myostatin inhibits insulin signaling in muscle 
cells34•35 , we performed a parallel study on insulin signaling in hepatocytes and 
C2C 12 myoblasts, each with ectopic expression of the identical FL-mstn 
construct. As shown in Figure 6A, our results faithfully reproduced the previous 
reports that myostatin inhibits insulin-induced activation of Akt at both Th308 
and Ser473 residues in C2C12 myoblasts34-36 . Interestingly, we also found that 
confluent C2C12 cells exhibited very high basal mTOR activity, evidenced by 
robust phosphorylation of phosphor-mTOR and its downstream target 4EBP1 
and 86. Adding exogenous insulin did not cause further increase in mTOR 
activity. This suggests the presence of an alternative mechanism to activate the 
mTOR pathway in confluent C2C12 myoblasts independent of insulin-induced 
Akt activation. However, expression of ectopic myostatin was able to reduce 
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phosphor-mTOR and phosphor-4E8P1 under both basal and insulin-stimulated 
conditions as well as to reduce phosphor-86 in the presence of insulin (Figure 
6A). Under otherwise identical conditions, exactly opposite results were found 
on myostatin-mediated cellular response to insulin in hepatocytes. As shown in 
Figure 68, ectopic expression of FL-mstn enhanced phosphorylation of AktTh308 , 
the upstream kinase for mTOR phosphorylation without affecting 
phosphorylation of Aktser473 , a downstream target of mTOR. As expected, 
expression of FL-mstn increased mTOR phosphorylation at 8er2448 in 
hepatocytes (Figure 68), in agreement with the results found in vivo (Figure 
38).This was associated with increased phorphorylation of its downstream 
target 4E8P1 and 86. Notably, phosphorylation of G8KI3 at 8er9 residue, 
another downstream target of mTOR, was also increased in hepatocytes 
expressing FL-mstn (Figure 68) while it was not affected C2C12 myoblasts 
expressing ectopic FL-mstn (Figure 6A) . 
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Figure 6. Myostatin has opposite effect on insulin signaling in hepatocytes in 
comparison to myoblasts. (A) myostatin inhibits insulin signaling in C2C12 
myoblasts; C2C12 cells stably transfected with FL-mstn or pLPCX were grown to 
confluence in DMEM high glucose 10% FBS for 2 days. Medium was change to 1% 
FBS/DMEM high glucose before adding myostatin (1 OOng/ml , 3 h) and/or insulin (5 ng/ml, 
0.5 h). (B) myostatin enhances acute response to insulin-induced activation of 
selected anabolic signals including mTOR and its downstream 4-EBP1 and S6 and 
GSK3b, in hepatocytes. MMHD3 cells stably transfected with FL-mstn or pLPCX were 
grown to confluence in 10% FBS without GF supplement for 48 h. Medium was changed 
to 1% FBS/RPMI before added myostatin (1 OOng/ml, 3 h) and/or insulin (5 ng/ml , 0.5 h). 
Myostatin-induced pro-lipogenic gene expression profile is abolished by 
inhibition of mTOR. 
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While the role of SREBP-1c in hepatic lipogenesis is well established , how this 
pathway is linked to insulin signaling remains elusive. After revealing that 
myostatin activated both SREBP-1 c and mTOR, we tested whether mTOR, the 
key element in insulin-regulated anabolic metabolism, may participate in 
activation of the SREBP-1 c pathway. As shown in Figure 7 A, expressfon of FL-
mstn increased nuclear SREBP 1 c in hepatocytes, which is consistent with our 
finding in vitro (Figure 3C) and this activation was largely blocked by rapamycin, 
the well-known mTOR inhibitor. As shown in Figure 78, ectopic expression of 
FL-mstn also increased expression of ACC, FAS, and SCD-1, all downstream 
target genes of SREBP-1 c, by> 3 fold . Blocking mTOR activation by rapamycin 
prevents myostatin-associated increase of these SREBP-1 c downstream 
lipogenic enzymes. These all suggest that myostatin promotes the lipogenic 
effect of insulin by enhancing nuclear translocation of SREBP-1 c, the master 
lipogenic transcription factor and increases expression its downstream target 
genes. This effect seems to be associated with myostatin-related mTOR 
activation. 
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Figure 7. Myostatin enhances SREBP-1 c expression in hepatocytes and rapamycin 
blocks this increase (A). Myostatin also increases expression of ACC, FAS and SCD-1 , 
downstream target genes of SREBP-1 C and this promotion was found to be blunted by 
rapamycin (B). 
MMHD3 cells stably transfected with FL-mstn or pLPCX were grown to confluence in 
10% FBS without GF supplement for 48 h and re-freshed a night before. With 1% 
FBS/RPMI, myostatin (100ng/ml), and/or rapamycin (10, 25, SOnM) was added for 3 
hours. Insulin (Sng/ml) was added 30 min before cells were extracted to mRNA. 
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DISCUSSION 
Here we showed severa l important new findings to the field of myostatin-related 
studies. First, we provided multiple lines of evidence to demonstrate that 
hepatocytes can be a direct target of myostatin, either provided as recombinant 
mature peptide dimmer or derived from ectopically expressed full-length protein. 
Secondly, we show that short-term exposure to myostatin in vivo increased liver 
insulin sensitivity in association with activation of SREBP-1 c and expression of 
its downstream lipogenic enzymes. This effect was recapitulated in cultured 
hepatocytes and was found to be mTOR-dependent. Finally, we have 
demonstrated that long-term myostatin blockade attenuated diet-induced liver 
fat accumulation and alleviated liver-specific insulin resistance . Although 
metabolic protection had been well reported in mice with genetic deletion or 
transgenic manipulation of myostatin 13-15•19•21 •23 , our study confirms that similar 
protection can be achieved by AAV-mediated gene transfer of a myostatin-
specific inhibitor, a strategy with great potential for clinical implications37. 
Our findings seem to contrad ict the widely accepted consensus that myostatin 
is a potent direct inhibitor of the Akt/mTOR pathway downstream of insulin or 
IGF-1 signaling. However, most of these prior studies were conducted in 
skeletal or cardiac muscle or cultured myogenic cells34-36·38-42· A few studies 
reported an acute negative impact of myostatin on liver Akt phosphorylation21 •22 . 
In these studies, recombinant myostatin was injected subcutaneously and 
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muscle and systemic insulin resistance was reported in parallel21 •22 . It is not 
known whether the discrepancy can be related to the functional difference 
between the recombinant myostatin mature peptide used in the previous study 
and the full length myostatin expressed and edited in vivo as described in the 
current study. Also, it is not clear whether the reported acute impairment of 
hepatic insulin signaling by myostatin was secondary to its effect on muscle and 
other remote organs. In our current study, we used virus-mediated del ivery of 
full-length myostatin and its propeptide via i.v. injection. The ectopic gene 
products were almost exclusively expressed in the liver. This approach 
bypassed the possible complications related to the off-target effects associated 
with the subcutaneously injection of recombinant proteins. In addition , we have 
confi rmed our in vivo observations in vitro, using both recombinant myostatin 
and ectopic expression of full-length myostatin in cultured hepatocytes. Also , 
our parallel study on insulin signaling in hepatocytes and C2C12 myoblasts 
which showed that myostatin induces opposite response to insulin in 
hepatocytes and myoblast. 
The signaling pathways for myostatin have been studied and can be divided 
into Smad-mediated and Non-Smad pathways43 . Myostatin is believed to signal 
by a mechanism similar to that of TGF-13 and is originally elucidated to initiate 
specific intracellular signals by Smad proteins. It has been reported that Smad 2 
and Smad 3 mediate signaling for myostatin30·44 . Aside from the canonical 
Smad-mediated signal pathway, there are various Non-Smad pathways that 
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have been shown to participate in myostatin signal transduction45 . Additional 
experiments will be required to elucidate whether myostatin-induced activation 
of mTOR-SREBP-1c axis is dependent on the canonical Smad2/3 signaling 
pathway activated by myostatin . 
Furthermore, our findings that myostatin acutely activated AktlmTOR/SREBP-1c 
pathway is consistent with the hypothesis that myostatin promotes hepatic 
lipogenesis while its blockade protects against diet-induced fatty liver 
development. The latter prediction has been widely validated by multiple 
research groups using genetic deletion of myostatin 13·15·21 . More recently , at 
least two different groups have demonstrated that mTOR is required for hepatic 
lipogenesis41·42 . Emerging evidence now placed SREBP-1c as a downstream 
target of AktlmTOR, especially the rapamycin-sensitive mTOR complex 1 
(mTORC1 )29.45-49 . This is in line with our results of Figure 7 which re-affirms a 
critical role of mTOR in myostatin-induced activation of SREBP-1c and lipogenic 
gene expression . The exact mechanism by which AktlmTOR regulates SREBP-
1 cis still controversial. There is evidence that Akt may, independent of mTOR, 
stabilize SREBP1 c through inhibition (phosphorylation) of GSK347·50·51 . 
Interestingly, while we detected a myostatin-induced increase in phosphor-
GSK313 in hepatocytes under basal and insulin-stimulated conditions , the role of 
this kinase here is not clear since myostatin-induced pro-lipogenic expression 
was nearly completely blunted by even low dosage rapamycin , implying a 
stronger involvement of mTORC1 . The main downstream targets of mTORC1 
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are S6Ks and the 4E-BPs, which play important roles in translation initiation and 
protein synthesis. However, exactly how each is linked to SREBP1 cremains 
elusive. Hence, our observation that myostatin increased phosphor-86 and 
phosphor-4E-BP1 are more likely markers for the activated mTORC1 pathway 
rather than providing a mechanistic link to the pro-lipogenic effect of myostatin. 
More recently, it was shown that mTORC1 regulates SREBP by controlling the 
nuclear entry of lip in 1, a phosphatidic acid phosphatase. Whether this pathway 
is involved in myostatin-mediated metabolic regulation remains to be 
determined. 
In conclusion, we provide multiple lines of evidence that myostatin directly 
interacts with hepatocytes in this work. Myostatin enhances insulin signaling in 
both cultured hepatocytes and in mouse liver. Myostatin promotes the lipogenic 
effect of insulin by enhancing nuclear translocation of SREBP-1 c and increasing 
expression of its downstream lipogenic genes. This effect was found to be 
associated with myostatin-related mTOR activation. Last but not least, our 
results suggest that AAV-mediated gene transfer of a myostatin-specific 
inhibitor may have a great potential to serve as an effective means for NAFLD 
treatment. 
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